Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19....

Descripción completa

Detalles Bibliográficos
Autores principales: Frankel, Arthur E., Reddy, Renuka, DeSuza, Kayla R., Deeb, Khaled, Carlin, Aaron F., Smith, Davey, Xie, Yushuang, Naik, Eknath, Silver, Richard T., Hasselbalch, Hans C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077319/
https://www.ncbi.nlm.nih.gov/pubmed/33936671
http://dx.doi.org/10.1002/ccr3.3997
Descripción
Sumario:An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.

Ejemplares similares